Zacks: Brokerages Anticipate Crispr Therapeutics AG (NASDAQ:CRSP) to Announce -$0.95 Earnings Per Share

Share on StockTwits

Brokerages predict that Crispr Therapeutics AG (NASDAQ:CRSP) will report earnings of ($0.95) per share for the current quarter, according to Zacks. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.78) and the lowest estimate coming in at ($1.09). Crispr Therapeutics posted earnings of ($1.07) per share during the same quarter last year, which would suggest a positive year over year growth rate of 11.2%. The firm is expected to announce its next earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of ($3.85) per share for the current fiscal year, with EPS estimates ranging from ($4.22) to ($3.37). For the next fiscal year, analysts expect that the business will report earnings of ($4.04) per share, with EPS estimates ranging from ($5.59) to ($2.94). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, July 29th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.84). Crispr Therapeutics had a negative return on equity of 51.49% and a negative net margin of 15,136.56%. The company had revenue of $0.32 million during the quarter, compared to the consensus estimate of $47.57 million. During the same quarter last year, the firm earned ($0.82) EPS. The business’s revenue for the quarter was down 70.8% on a year-over-year basis.

Several research firms recently weighed in on CRSP. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. William Blair restated a “hold” rating on shares of Crispr Therapeutics in a research report on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $62.00 price objective on shares of Crispr Therapeutics in a research report on Wednesday, July 31st. Barclays boosted their price objective on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Finally, Roth Capital upped their target price on shares of Crispr Therapeutics from $50.00 to $65.00 in a research report on Tuesday, July 30th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $57.25.

CRSP stock traded down $1.02 during trading on Thursday, hitting $39.03. The company had a trading volume of 22,154 shares, compared to its average volume of 521,656. The company has a quick ratio of 13.96, a current ratio of 13.96 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $42.84 and a 200-day moving average price of $43.37. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $53.90. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -11.34 and a beta of 3.11.

Several institutional investors have recently modified their holdings of CRSP. Nikko Asset Management Americas Inc. raised its position in shares of Crispr Therapeutics by 324.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after acquiring an additional 1,430,364 shares during the last quarter. ARK Investment Management LLC raised its position in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after acquiring an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at $5,165,000. Institutional investors own 50.23% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: Blockchain

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Lowers Calumet Specialty Products Partners, L.P  to Sell
Zacks Investment Research Lowers Calumet Specialty Products Partners, L.P to Sell
Bank of America Boosts Ping Identity  Price Target to $24.00
Bank of America Boosts Ping Identity Price Target to $24.00
Catchmark Timber Trust  Rating Lowered to Hold at ValuEngine
Catchmark Timber Trust Rating Lowered to Hold at ValuEngine
MGM Resorts International  Short Interest Down 16.9% in October
MGM Resorts International Short Interest Down 16.9% in October
Lamar Advertising Co  Expected to Announce Earnings of $1.68 Per Share
Lamar Advertising Co Expected to Announce Earnings of $1.68 Per Share
Brinker International, Inc.  Sees Large Decline in Short Interest
Brinker International, Inc. Sees Large Decline in Short Interest


© 2006-2019 Ticker Report